FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Evidence for efficacy is based on the results from the BRUIN study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast Cancer Highlight Priority Molecular Targets for Future Clinical Trials
Genomic features of HRD, PIK3CA mutations with copy number amplifications, and copy number amplifications are enriched in young women
Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with ctDNA Matched Therapy as Recommended by a Molecular Tumour Board
Findings from the genomic profiling of ctDNA in patients included in the STING precision medicine study
FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
FDA also approved the Guardant360 CDx assay as a companion diagnostic
A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is Associated with Immunotherapy Response
New measure of tumour mutational burden based on genomic regions unlikely to undergo loss
Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients with BRAF V600E-mutated Colorectal Cancer
Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition
FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC
Evidence for efficacy is based on the results from the KEYNOTE-091 study
Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint Inhibitors in the Treatment of Advanced NSCLC, Particularly Among the Older Patients
Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age
EMA Recommends Extension of Indications for Darolutamide
New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy
Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer
Findings from the GALAXY, an observational arm of the ongoing CIRCULATE-Japan study
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
Evidence for efficacy is based on the results from the SEQUOIA and ALPINE studies
Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable Colon Cancer, Producing Marked Histopathologic Downstaging and Disease Control
Findings from the FOxTROT study